Remibrutinib Showed a Favorable Safety Profile and Sustained Efficacy in Japanese Patients with Chronic Spontaneous Urticaria Over 52 Weeks.
- DOI
- 10.1007/s13555-026-01666-5
- Published
- 2026 Mar
- Container
- Dermatology and therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s13555-026-01666-5,
title = {Remibrutinib Showed a Favorable Safety Profile and Sustained Efficacy in Japanese Patients with Chronic Spontaneous Urticaria Over 52 Weeks.},
author = {Hayama K and Chinuki Y and Yagami A and Kume A and Morita A and Miyazu S and Lheritier K and Jaskiewicz L and Haemmerle S and Hide M},
year = {2026},
journal = {Dermatology and therapy},
doi = {10.1007/s13555-026-01666-5},
url = {https://doi.org/10.1007/s13555-026-01666-5}
}RIS
TY - JOUR TI - Remibrutinib Showed a Favorable Safety Profile and Sustained Efficacy in Japanese Patients with Chronic Spontaneous Urticaria Over 52 Weeks. AU - Hayama K AU - Chinuki Y AU - Yagami A AU - Kume A AU - Morita A AU - Miyazu S AU - Lheritier K AU - Jaskiewicz L AU - Haemmerle S AU - Hide M PY - 2026 JO - Dermatology and therapy DO - 10.1007/s13555-026-01666-5 UR - https://doi.org/10.1007/s13555-026-01666-5 ER -
APA
K, H., Y, C., A, Y., A, K., A, M., S, M., K, L., L, J., S, H., & M, H. (2026). Remibrutinib Showed a Favorable Safety Profile and Sustained Efficacy in Japanese Patients with Chronic Spontaneous Urticaria Over 52 Weeks.. Dermatology and therapy. https://doi.org/10.1007/s13555-026-01666-5
Source records
- pubmed · retrieved 2026-09-26T04:13:34.327Z